Literature DB >> 9334732

The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression.

N L Michael1, L G Louie, A L Rohrbaugh, K A Schultz, D E Dayhoff, C E Wang, H W Sheppard.   

Abstract

Entry of human immunodeficiency virus type 1 (HIV-1) into target cells requires both CD4 (ref. 1, 2) and one of a growing number of G-protein-coupled seven-transmembrane receptors. Viruses predominantly use one, or occasionally both, of the major co-receptors CCR5 or CXCR4, although other receptors, including CCR2B and CCR3, function as minor co-receptors. CCR3 appears critical in central nervous system infection. A 32-base pair inactivating deletion in CCR5 (delta 32) common to Northern European populations has been associated with reduced, but not absolute, HIV-1 transmission risk and delayed disease progression. A more commonly distributed transition causing a valine to isoleucine switch in transmembrane domain I of CCR2B (64I) with unknown functional consequences was recently shown to delay disease progression but not reduce infection risk. Although we confirm the lack of association of CCR2B 64I with transmission, we cannot confirm the association with delayed progression. Although subjects with CCR5 delta 32 defects had significantly reduced median viral load at study entry, providing a plausible explanation for the association with delayed progression, this association was not seen with CCR2B 64I. Further studies are needed to define the role of CCR2B64I in HIV pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9334732     DOI: 10.1038/nm1097-1160

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  39 in total

1.  Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic.

Authors:  E Gonzalez; R Dhanda; M Bamshad; S Mummidi; R Geevarghese; G Catano; S A Anderson; E A Walter; K T Stephan; M F Hammer; A Mangano; L Sen; R A Clark; S S Ahuja; M J Dolan; S K Ahuja
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 2.  Host genetic factors in susceptibility to HIV-1 infection and progression to AIDS.

Authors:  Koushik Chatterjee
Journal:  J Genet       Date:  2010-04       Impact factor: 1.166

3.  CD192 gene variant and susceptibility to cervical cancer: a meta analysis.

Authors:  Yuying Chen; Xinli Liu; Min Chen; Jian Shen; Yanqi Lu; Lei Yu; Shouying Liu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro.

Authors:  Janelle R Salkowitz; Shannon E Bruse; Howard Meyerson; Hernan Valdez; Donald E Mosier; Clifford V Harding; Peter A Zimmerman; Michael M Lederman
Journal:  Clin Immunol       Date:  2003-09       Impact factor: 3.969

5.  A review of the clinical pharmacology of maraviroc. Introduction.

Authors:  Marta Boffito; Samantha Abel
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335

6.  Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression.

Authors:  Jianming Tang; Brent Shelton; Nina J Makhatadze; Yuting Zhang; Margaret Schaen; Leslie G Louie; James J Goedert; Eric C Seaberg; Joseph B Margolick; John Mellors; Richard A Kaslow
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  Maternal SDF1 3'A polymorphism is associated with increased perinatal human immunodeficiency virus type 1 transmission.

Authors:  G C John; C Rousseau; T Dong; S Rowland-Jones; R Nduati; D Mbori-Ngacha; T Rostron; J K Kreiss; B A Richardson; J Overbaugh
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

8.  Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype.

Authors:  E E Nakayama; Y Hoshino; X Xin; H Liu; M Goto; N Watanabe; H Taguchi; A Hitani; A Kawana-Tachikawa; M Fukushima; K Yamada; W Sugiura; S I Oka; A Ajisawa; H Sato; Y Takebe; T Nakamura; Y Nagai; A Iwamoto; T Shioda
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 9.  Chemokine receptors and chemokines in HIV infection.

Authors:  A Garzino-Demo; A L DeVico; R C Gallo
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

10.  Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5.

Authors:  T Shioda; E E Nakayama; Y Tanaka; X Xin; H Liu; A Kawana-Tachikawa; A Kato; Y Sakai; Y Nagai; A Iwamoto
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.